A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels
NCT ID: NCT00327691
Last Updated: 2007-05-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
8600 participants
INTERVENTIONAL
1998-04-30
2004-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
35 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Alabaster, Alabama, United States
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Hoover, Alabama, United States
Pfizer Investigational Site
Montgomery, Alabama, United States
Pfizer Investigational Site
Mesa, Arizona, United States
Pfizer Investigational Site
Mesa, Arizona, United States
Pfizer Investigational Site
Burbank, California, United States
Pfizer Investigational Site
Camp Pendleton, California, United States
Pfizer Investigational Site
Fresno, California, United States
Pfizer Investigational Site
La Jolla, California, United States
Pfizer Investigational Site
Loma Linda, California, United States
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
Los Angeles, California, United States
Pfizer Investigational Site
Modesto, California, United States
Pfizer Investigational Site
Pasadena, California, United States
Pfizer Investigational Site
Rancho Mirage, California, United States
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
San Francisco, California, United States
Pfizer Investigational Site
San Francisco, California, United States
Pfizer Investigational Site
Santa Rosa, California, United States
Pfizer Investigational Site
Stanford, California, United States
Pfizer Investigational Site
Aurora, Colorado, United States
Pfizer Investigational Site
Denver, Colorado, United States
Pfizer Investigational Site
Denver, Colorado, United States
Pfizer Investigational Site
Denver, Colorado, United States
Pfizer Investigational Site
Bridgeport, Connecticut, United States
Pfizer Investigational Site
Hartford, Connecticut, United States
Pfizer Investigational Site
New Britain, Connecticut, United States
Pfizer Investigational Site
Newark, Delaware, United States
Pfizer Investigational Site
Washington D.C., District of Columbia, United States
Pfizer Investigational Site
Clearwater, Florida, United States
Pfizer Investigational Site
Gainsville, Florida, United States
Pfizer Investigational Site
Gainsville, Florida, United States
Pfizer Investigational Site
Hollywood, Florida, United States
Pfizer Investigational Site
Inverness, Florida, United States
Pfizer Investigational Site
Lakeland, Florida, United States
Pfizer Investigational Site
Miami, Florida, United States
Pfizer Investigational Site
Miami, Florida, United States
Pfizer Investigational Site
Ocala, Florida, United States
Pfizer Investigational Site
Orlando, Florida, United States
Pfizer Investigational Site
Port Charlotte, Florida, United States
Pfizer Investigational Site
Sarasota, Florida, United States
Pfizer Investigational Site
Stuart, Florida, United States
Pfizer Investigational Site
Tamarac, Florida, United States
Pfizer Investigational Site
The Villages, Florida, United States
Pfizer Investigational Site
Atlanta, Georgia, United States
Pfizer Investigational Site
Canton, Georgia, United States
Pfizer Investigational Site
Berwyn, Illinois, United States
Pfizer Investigational Site
Blue Island, Illinois, United States
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Chicago, Illinois, United States
Pfizer Investigational Site
Du Quoin, Illinois, United States
Pfizer Investigational Site
Evanston, Illinois, United States
Pfizer Investigational Site
Lake Forest, Illinois, United States
Pfizer Investigational Site
Marion, Illinois, United States
Pfizer Investigational Site
Pekin, Illinois, United States
Pfizer Investigational Site
Peoria, Illinois, United States
Pfizer Investigational Site
Peoria, Illinois, United States
Pfizer Investigational Site
Beech Grove, Indiana, United States
Pfizer Investigational Site
Evansville, Indiana, United States
Pfizer Investigational Site
Fort Wayne, Indiana, United States
Pfizer Investigational Site
Fort Wayne, Indiana, United States
Pfizer Investigational Site
Jeffersonville, Indiana, United States
Pfizer Investigational Site
Scottsburg, Indiana, United States
Pfizer Investigational Site
Des Moines, Iowa, United States
Pfizer Investigational Site
Iowa City, Iowa, United States
Pfizer Investigational Site
Kansas City, Kansas, United States
Pfizer Investigational Site
Lathe, Kansas, United States
Pfizer Investigational Site
Overland Park, Kansas, United States
Pfizer Investigational Site
Wichita, Kansas, United States
Pfizer Investigational Site
Edgewood, Kentucky, United States
Pfizer Investigational Site
Erlanger, Kentucky, United States
Pfizer Investigational Site
Louisville, Kentucky, United States
Pfizer Investigational Site
Marrero, Louisiana, United States
Pfizer Investigational Site
New Orleans, Louisiana, United States
Pfizer Investigational Site
New Orleans, Louisiana, United States
Pfizer Investigational Site
Portland, Maine, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Bel Air, Maryland, United States
Pfizer Investigational Site
Westminster, Maryland, United States
Pfizer Investigational Site
Boston, Massachusetts, United States
Pfizer Investigational Site
Boston, Massachusetts, United States
Pfizer Investigational Site
Burlington, Massachusetts, United States
Pfizer Investigational Site
Dearborn, Michigan, United States
Pfizer Investigational Site
Detroit, Michigan, United States
Pfizer Investigational Site
Farmington Hill, Michigan, United States
Pfizer Investigational Site
Sterling Heights, Michigan, United States
Pfizer Investigational Site
West Bloomfield, Michigan, United States
Pfizer Investigational Site
Duluth, Minnesota, United States
Pfizer Investigational Site
Edina, Minnesota, United States
Pfizer Investigational Site
Maplewood, Minnesota, United States
Pfizer Investigational Site
Minneapolis, Minnesota, United States
Pfizer Investigational Site
Saint Paul, Minnesota, United States
Pfizer Investigational Site
Kansas City, Missouri, United States
Pfizer Investigational Site
St Louis, Missouri, United States
Pfizer Investigational Site
St Louis, Missouri, United States
Pfizer Investigational Site
St Louis, Missouri, United States
Pfizer Investigational Site
St Louis, Missouri, United States
Pfizer Investigational Site
St Louis, Missouri, United States
Pfizer Investigational Site
Papillion, Nebraska, United States
Pfizer Investigational Site
Manchester, New Hampshire, United States
Pfizer Investigational Site
New Brunswick, New Jersey, United States
Pfizer Investigational Site
Albany, New York, United States
Pfizer Investigational Site
Brooklyn, New York, United States
Pfizer Investigational Site
Hawthorne, New York, United States
Pfizer Investigational Site
Manlius, New York, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
Rochester, New York, United States
Pfizer Investigational Site
Rochester, New York, United States
Pfizer Investigational Site
Rochester, New York, United States
Pfizer Investigational Site
Syracuse, New York, United States
Pfizer Investigational Site
Syracuse, New York, United States
Pfizer Investigational Site
Valhalla, New York, United States
Pfizer Investigational Site
Asheville, North Carolina, United States
Pfizer Investigational Site
Durham, North Carolina, United States
Pfizer Investigational Site
Eden, North Carolina, United States
Pfizer Investigational Site
Winston-Salem, North Carolina, United States
Pfizer Investigational Site
Beachwood, Ohio, United States
Pfizer Investigational Site
Cincinnati, Ohio, United States
Pfizer Investigational Site
Cincinnati, Ohio, United States
Pfizer Investigational Site
Cincinnati, Ohio, United States
Pfizer Investigational Site
Cleveland, Ohio, United States
Pfizer Investigational Site
Cleveland, Ohio, United States
Pfizer Investigational Site
Columbus, Ohio, United States
Pfizer Investigational Site
Columbus, Ohio, United States
Pfizer Investigational Site
Kettering, Ohio, United States
Pfizer Investigational Site
Lorain, Ohio, United States
Pfizer Investigational Site
Sandusky, Ohio, United States
Pfizer Investigational Site
Oklahoma City, Oklahoma, United States
Pfizer Investigational Site
Tulsa, Oklahoma, United States
Pfizer Investigational Site
Tulsa, Oklahoma, United States
Pfizer Investigational Site
Tulsa, Oklahoma, United States
Pfizer Investigational Site
Eugene, Oregon, United States
Pfizer Investigational Site
Portland, Oregon, United States
Pfizer Investigational Site
Portland, Oregon, United States
Pfizer Investigational Site
Allentown, Pennsylvania, United States
Pfizer Investigational Site
Allentown, Pennsylvania, United States
Pfizer Investigational Site
Lansdale, Pennsylvania, United States
Pfizer Investigational Site
Lehighton, Pennsylvania, United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States
Pfizer Investigational Site
Philadelphia, Pennsylvania, United States
Pfizer Investigational Site
Pittsburgh, Pennsylvania, United States
Pfizer Investigational Site
Sellersville, Pennsylvania, United States
Pfizer Investigational Site
Pawtucket, Rhode Island, United States
Pfizer Investigational Site
Providence, Rhode Island, United States
Pfizer Investigational Site
Charleston, South Carolina, United States
Pfizer Investigational Site
Sioux Falls, South Dakota, United States
Pfizer Investigational Site
Sioux Falls, South Dakota, United States
Pfizer Investigational Site
Memphis, Tennessee, United States
Pfizer Investigational Site
Memphis, Tennessee, United States
Pfizer Investigational Site
Memphis, Tennessee, United States
Pfizer Investigational Site
Memphis, Tennessee, United States
Pfizer Investigational Site
Nashville, Tennessee, United States
Pfizer Investigational Site
Nashville, Tennessee, United States
Pfizer Investigational Site
Austin, Texas, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
Denton, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
Lackland Air Force Base, Texas, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
Salt Lake City, Utah, United States
Pfizer Investigational Site
Burlington, Vermont, United States
Pfizer Investigational Site
Richmond, Virginia, United States
Pfizer Investigational Site
Richmond, Virginia, United States
Pfizer Investigational Site
Seattle, Washington, United States
Pfizer Investigational Site
Milwaukee, Wisconsin, United States
Pfizer Investigational Site
St Leonards, New South Wales, Australia
Pfizer Investigational Site
Auchenflower, Queensland, Australia
Pfizer Investigational Site
Brisbane, Queensland, Australia
Pfizer Investigational Site
Chermside, Queensland, Australia
Pfizer Investigational Site
Greenslopes, Queensland, Australia
Pfizer Investigational Site
Herston, Queensland, Australia
Pfizer Investigational Site
Milton, Queensland, Australia
Pfizer Investigational Site
Adelaide, South Australia, Australia
Pfizer Investigational Site
Bedford Park, South Australia, Australia
Pfizer Investigational Site
Hobart, Tasmania, Australia
Pfizer Investigational Site
Clayton, Victoria, Australia
Pfizer Investigational Site
Parkville, Victoria, Australia
Pfizer Investigational Site
Prahran, Victoria, Australia
Pfizer Investigational Site
Nedlands, Western Australia, Australia
Pfizer Investigational Site
Feldkirch, , Austria
Pfizer Investigational Site
Oberpullendorf, , Austria
Pfizer Investigational Site
Vienna, , Austria
Pfizer Investigational Site
Vienna, , Austria
Pfizer Investigational Site
Aalst, , Belgium
Pfizer Investigational Site
Antwerp, , Belgium
Pfizer Investigational Site
Genk, , Belgium
Pfizer Investigational Site
Genk, , Belgium
Pfizer Investigational Site
Godinne, , Belgium
Pfizer Investigational Site
Leuven, , Belgium
Pfizer Investigational Site
Lommel, , Belgium
Pfizer Investigational Site
Neerpelt, , Belgium
Pfizer Investigational Site
Calgary, Alberta, Canada
Pfizer Investigational Site
Calgary, Alberta, Canada
Pfizer Investigational Site
Edmonton, Alberta, Canada
Pfizer Investigational Site
Edmonton, Alberta, Canada
Pfizer Investigational Site
Nanaimo, British Columbia, Canada
Pfizer Investigational Site
Vancouver, British Columbia, Canada
Pfizer Investigational Site
Victoria, British Columbia, Canada
Pfizer Investigational Site
Winnipeg, Manitoba, Canada
Pfizer Investigational Site
St. John's, Newfoundland and Labrador, Canada
Pfizer Investigational Site
Halifax, Nova Scotia, Canada
Pfizer Investigational Site
Greater Sudbury, Ontario, Canada
Pfizer Investigational Site
Hamilton, Ontario, Canada
Pfizer Investigational Site
London, Ontario, Canada
Pfizer Investigational Site
Ottawa, Ontario, Canada
Pfizer Investigational Site
Toronto, Ontario, Canada
Pfizer Investigational Site
Chicoutimi, Quebec, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Montreal, Quebec, Canada
Pfizer Investigational Site
Québec, Quebec, Canada
Pfizer Investigational Site
Sherbrooke, Quebec, Canada
Pfizer Investigational Site
St-foy, Quebec, Canada
Pfizer Investigational Site
Pessac, Cedex, France
Pfizer Investigational Site
Agen, , France
Pfizer Investigational Site
Bordeaux, , France
Pfizer Investigational Site
Brest, , France
Pfizer Investigational Site
Clermont-Ferrand, , France
Pfizer Investigational Site
Lyon, , France
Pfizer Investigational Site
Marseille, , France
Pfizer Investigational Site
Paris, , France
Pfizer Investigational Site
Rennes, , France
Pfizer Investigational Site
Roubaix, , France
Pfizer Investigational Site
Strasbourg, , France
Pfizer Investigational Site
Toulouse, , France
Pfizer Investigational Site
Toulouse, , France
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Essen, , Germany
Pfizer Investigational Site
Hamburg, , Germany
Pfizer Investigational Site
Schwerte, , Germany
Pfizer Investigational Site
Tostedt, , Germany
Pfizer Investigational Site
Würzburg, , Germany
Pfizer Investigational Site
Cork, , Ireland
Pfizer Investigational Site
Dublin, , Ireland
Pfizer Investigational Site
Bologna, , Italy
Pfizer Investigational Site
Bologna, , Italy
Pfizer Investigational Site
Cuneo, , Italy
Pfizer Investigational Site
Florence, , Italy
Pfizer Investigational Site
Napoli, , Italy
Pfizer Investigational Site
Rome, , Italy
Pfizer Investigational Site
Udine, , Italy
Pfizer Investigational Site
's-Hertogenbosch, , Netherlands
Pfizer Investigational Site
Alkmaar, , Netherlands
Pfizer Investigational Site
Amersfoort, , Netherlands
Pfizer Investigational Site
Amsterdam, , Netherlands
Pfizer Investigational Site
Breda, , Netherlands
Pfizer Investigational Site
Eindhoven, , Netherlands
Pfizer Investigational Site
Enschede, , Netherlands
Pfizer Investigational Site
Groningen, , Netherlands
Pfizer Investigational Site
Groningen, , Netherlands
Pfizer Investigational Site
Leiden, , Netherlands
Pfizer Investigational Site
Nieuwegein, , Netherlands
Pfizer Investigational Site
Nijmegen, , Netherlands
Pfizer Investigational Site
Zwolle, , Netherlands
Pfizer Investigational Site
Zwolle, , Netherlands
Pfizer Investigational Site
Johannesburg, Gauteng, South Africa
Pfizer Investigational Site
Sunninghill, Gauteng, South Africa
Pfizer Investigational Site
Bloemfontein, , South Africa
Pfizer Investigational Site
Cape Town, , South Africa
Pfizer Investigational Site
Cape Town, , South Africa
Pfizer Investigational Site
Parow, , South Africa
Pfizer Investigational Site
Córdoba, CORDOBA, Spain
Pfizer Investigational Site
Madrid, Madrid, Spain
Pfizer Investigational Site
Seville, Sevilla, Spain
Pfizer Investigational Site
Seville, Sevilla, Spain
Pfizer Investigational Site
Barcelona, , Spain
Pfizer Investigational Site
Barcelona, , Spain
Pfizer Investigational Site
Donostia / San Sebastian, , Spain
Pfizer Investigational Site
Madrid, , Spain
Pfizer Investigational Site
Madrid, , Spain
Pfizer Investigational Site
Madrid, , Spain
Pfizer Investigational Site
Santiago de Compostela, , Spain
Pfizer Investigational Site
Valladolid, , Spain
Pfizer Investigational Site
Zaragoza, , Spain
Pfizer Investigational Site
Bern, , Switzerland
Pfizer Investigational Site
Geneva, , Switzerland
Pfizer Investigational Site
Lausanne, , Switzerland
Pfizer Investigational Site
Lugano, , Switzerland
Pfizer Investigational Site
Sankt Gallen, , Switzerland
Pfizer Investigational Site
Romford, ESSEX, United Kingdom
Pfizer Investigational Site
London, GREATER LONDON, United Kingdom
Pfizer Investigational Site
London, GREATER LONDON, United Kingdom
Pfizer Investigational Site
London, GREATER LONDON, United Kingdom
Pfizer Investigational Site
Aldershot, HAMPSHIRE, United Kingdom
Pfizer Investigational Site
Farnborough, KENT, United Kingdom
Pfizer Investigational Site
Blackpool, LANCASHIRE, United Kingdom
Pfizer Investigational Site
Leicester, LEICESTERSHIRE, United Kingdom
Pfizer Investigational Site
London, MIDDLESEX, United Kingdom
Pfizer Investigational Site
Coventry, West Midlands, United Kingdom
Pfizer Investigational Site
Coventry, WEST Midlands, United Kingdom
Pfizer Investigational Site
Swindon, Wiltshire, United Kingdom
Pfizer Investigational Site
Barnet, , United Kingdom
Pfizer Investigational Site
Glasgow, , United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Pfizer Investigational Site
London, , United Kingdom
Pfizer Investigational Site
Paisley, , United Kingdom
Pfizer Investigational Site
, ,
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Waters DD, LaRosa JC, Barter P, Fruchart JC, Gotto AM Jr, Carter R, Breazna A, Kastelein JJ, Grundy SM. Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol. 2006 Nov 7;48(9):1793-9. doi: 10.1016/j.jacc.2006.07.041. Epub 2006 Oct 17.
Tunnicliffe DJ, Palmer SC, Cashmore BA, Saglimbene VM, Krishnasamy R, Lambert K, Johnson DW, Craig JC, Strippoli GF. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev. 2023 Nov 29;11(11):CD007784. doi: 10.1002/14651858.CD007784.pub3.
Vogt L, Bangalore S, Fayyad R, Melamed S, Hovingh GK, DeMicco DA, Waters DD. Atorvastatin Has a Dose-Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Double-Blind Randomized Controlled Trials. J Am Heart Assoc. 2019 May 7;8(9):e010827. doi: 10.1161/JAHA.118.010827.
Bangalore S, Fayyad R, DeMicco DA, Colhoun HM, Waters DD. Body Weight Variability and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus. Circ Cardiovasc Qual Outcomes. 2018 Nov;11(11):e004724. doi: 10.1161/CIRCOUTCOMES.118.004724.
Kaasenbrood L, Ray KK, Boekholdt SM, Smulders YM, LaRosa JC, Kastelein JJP, van der Graaf Y, Dorresteijn JAN, Visseren FLJ. Estimated individual lifetime benefit from PCSK9 inhibition in statin-treated patients with coronary artery disease. Heart. 2018 Oct;104(20):1699-1705. doi: 10.1136/heartjnl-2017-312510. Epub 2018 Apr 5.
Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, Hovingh GK, Kastelein JJ, Melamed S, Barter P, Waters DD, Ray KK. Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. Circulation. 2018 Aug 21;138(8):770-781. doi: 10.1161/CIRCULATIONAHA.117.032318.
Ong KL, Waters DD, Fayyad R, Vogt L, Melamed S, DeMicco DA, Rye KA, Barter PJ. Relationship of High-Density Lipoprotein Cholesterol With Renal Function in Patients Treated With Atorvastatin. J Am Heart Assoc. 2018 Jan 22;7(2):e007387. doi: 10.1161/JAHA.117.007387.
Ports WC, Fayyad R, DeMicco DA, Laskey R, Wolk R. Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis. Clin Drug Investig. 2017 Aug;37(8):775-785. doi: 10.1007/s40261-017-0533-0.
Bangalore S, Fayyad R, Laskey R, DeMicco DA, Messerli FH, Waters DD. Body-Weight Fluctuations and Outcomes in Coronary Disease. N Engl J Med. 2017 Apr 6;376(14):1332-1340. doi: 10.1056/NEJMoa1606148.
Stam-Slob MC, van der Graaf Y, Greving JP, Dorresteijn JA, Visseren FL. Cost-Effectiveness of Intensifying Lipid-Lowering Therapy With Statins Based on Individual Absolute Benefit in Coronary Artery Disease Patients. J Am Heart Assoc. 2017 Feb 18;6(2):e004648. doi: 10.1161/JAHA.116.004648.
Deedwania PC, Pedersen TR, DeMicco DA, Breazna A, Betteridge DJ, Hitman GA, Durrington P, Neil A; TNT, CARDS and IDEAL Steering Committees and Investigators. Differing predictive relationships between baseline LDL-C, systolic blood pressure, and cardiovascular outcomes. Int J Cardiol. 2016 Nov 1;222:548-556. doi: 10.1016/j.ijcard.2016.07.201. Epub 2016 Jul 30.
Byun YS, Lee JH, Arsenault BJ, Yang X, Bao W, DeMicco D, Laskey R, Witztum JL, Tsimikas S; TNT Trial Investigators. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J Am Coll Cardiol. 2015 Apr 7;65(13):1286-1295. doi: 10.1016/j.jacc.2015.01.050.
Arsenault BJ, Barter P, DeMicco DA, Bao W, Preston GM, LaRosa JC, Grundy SM, Deedwania P, Greten H, Wenger NK, Shepherd J, Waters DD, Kastelein JJ; Treating to New Targets (TNT) Investigators. Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers. PLoS One. 2014 Dec 22;9(12):e114519. doi: 10.1371/journal.pone.0114519. eCollection 2014.
Dorresteijn JA, Boekholdt SM, van der Graaf Y, Kastelein JJ, LaRosa JC, Pedersen TR, DeMicco DA, Ridker PM, Cook NR, Visseren FL. High-dose statin therapy in patients with stable coronary artery disease: treating the right patients based on individualized prediction of treatment effect. Circulation. 2013 Jun 25;127(25):2485-93. doi: 10.1161/CIRCULATIONAHA.112.000712. Epub 2013 May 14.
Semb AG, Kvien TK, DeMicco DA, Fayyad R, Wun CC, LaRosa JC, Betteridge J, Pedersen TR, Holme I. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum. 2012 Sep;64(9):2836-46. doi: 10.1002/art.34524.
Huijgen R, Boekholdt SM, Arsenault BJ, Bao W, Davaine JM, Tabet F, Petrides F, Rye KA, DeMicco DA, Barter PJ, Kastelein JJ, Lambert G. Plasma PCSK9 levels and clinical outcomes in the TNT (Treating to New Targets) trial: a nested case-control study. J Am Coll Cardiol. 2012 May 15;59(20):1778-84. doi: 10.1016/j.jacc.2011.12.043.
Mora S, Wenger NK, Demicco DA, Breazna A, Boekholdt SM, Arsenault BJ, Deedwania P, Kastelein JJ, Waters DD. Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation. 2012 Apr 24;125(16):1979-87. doi: 10.1161/CIRCULATIONAHA.111.088591. Epub 2012 Mar 29.
Arsenault BJ, Boekholdt SM, Hovingh GK, Hyde CL, DeMicco DA, Chatterjee A, Barter P, Deedwania P, Waters DD, LaRosa JC, Pedersen TR, Kastelein JJ; TNT and IDEAL Investigators. The 719Arg variant of KIF6 and cardiovascular outcomes in statin-treated, stable coronary patients of the treating to new targets and incremental decrease in end points through aggressive lipid-lowering prospective studies. Circ Cardiovasc Genet. 2012 Feb 1;5(1):51-7. doi: 10.1161/CIRCGENETICS.111.960252. Epub 2011 Dec 1.
Arsenault BJ, Barter P, DeMicco DA, Bao W, Preston GM, LaRosa JC, Grundy SM, Deedwania P, Greten H, Wenger NK, Shepherd J, Waters DD, Kastelein JJ; TNT Study Investigators. Prediction of cardiovascular events in statin-treated stable coronary patients by lipid and nonlipid biomarkers. J Am Coll Cardiol. 2011 Jan 4;57(1):63-9. doi: 10.1016/j.jacc.2010.06.052.
Hyde CL, Macinnes A, Sanders FA, Thompson JF, Mazzarella RA, Faergeman O, van Wijk DF, Wood L, Lira M, Paciga SA. Genetic association of the CCR5 region with lipid levels in at-risk cardiovascular patients. Circ Cardiovasc Genet. 2010 Apr;3(2):162-8. doi: 10.1161/CIRCGENETICS.109.897793. Epub 2010 Feb 3.
Waters DD. Clinical insights from the Treating to New Targets trial. Prog Cardiovasc Dis. 2009 May-Jun;51(6):487-502. doi: 10.1016/j.pcad.2009.01.001.
Shepherd J, Kastelein JP, Bittner VA, Carmena R, Deedwania PC, Breazna A, Dobson S, Wilson DJ, Zuckerman AL, Wenger NK; Treating to New Targets Steering Committee and Investigators. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease. Mayo Clin Proc. 2008 Aug;83(8):870-9.
Shah SJ, Waters DD, Barter P, Kastelein JJ, Shepherd J, Wenger NK, DeMicco DA, Breazna A, LaRosa JC. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. J Am Coll Cardiol. 2008 May 20;51(20):1938-43. doi: 10.1016/j.jacc.2007.12.054.
Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, Wilson DJ, Zuckerman A, Wenger NK; TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008 Apr 15;51(15):1448-54. doi: 10.1016/j.jacc.2007.11.072.
Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC; Treating to New Targets Investigators. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007 Sep 27;357(13):1301-10. doi: 10.1056/NEJMoa064278.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A2581136
Identifier Type: -
Identifier Source: secondary_id
0981-117
Identifier Type: -
Identifier Source: org_study_id